Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc (NYSE:GSK) / Vir Biotechnology Inc (NASDAQ:VIR) and Eli Lilly And Co's (NYSE:LLY) COVID-19 treatments.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.